3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Urinary Bladder Neoplasms
1
Prostatic Neoplasms
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Non-Muscle Invasive Bladder Neoplasms
1
Myelodysplastic Syndromes
1
Metabolism, Inborn Errors
1
Lymphoma, Non-Hodgkin
1
Leukemia, Myeloid, Acute
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Leukemia
1
Immunologic Deficiency Syndromes
1
Hemoglobinopathies
1
Graft vs Host Disease
1
Congenital Bone Marrow Failure Syndromes
1
Carcinoma in Situ
1
Bone Marrow Failure Disorders
1
Anemia, Refractory, with Excess of Blasts
1
Interventions
pembrolizumab
44
Carboplatin
35
Paclitaxel
27
Specimen Handling
18
Cyclophosphamide
16
Capecitabine
16
Magnetic Resonance Spectroscopy
14
sacituzumab govitecan
13
Gemcitabine
13
Taxes
12
Biopsy
12
130-nm albumin-bound paclitaxel
11
Albumin-Bound Paclitaxel
9
Doxorubicin
8
olaparib
7
Nivolumab
7
fludarabine
6
Cisplatin
6
eribulin
5
atezolizumab
5
Radiotherapy
5
Docetaxel
5
durvalumab
4
Fulvestrant
4
Epirubicin
4
Bevacizumab
4
veliparib
3
famitinib
3
abemaciclib
3
Vinorelbine
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Triple Negative Breast Neoplasms
×
Clinical Trials, Phase I as Topic
×
90 days
×
Clear all
No trials found.